Cagrilintide 10 mg
Long-acting amylin analogue (AM833) · in phase 3, no approved product
Cagrilintide (AM833) is a long-acting analogue of human amylin, developed by Novo Nordisk. Amylin is a hormone the pancreas releases together with insulin after eating: it slows gastric emptying, curbs glucagon secretion, and acts on its own receptors (the calcitonin receptor paired with RAMP proteins) in the central nervous system to produce satiety. It is not the same as a GLP-1: semaglutide and other GLP-1 analogues act on a different receptor, the GLP-1 receptor, even though the end result -eating less and losing weight- looks similar. Natural human amylin tends to form fibrils, so cagrilintide carries modifications to stabilize it and a fatty acid chain so a single injection lasts a week. It has been tested alone (monotherapy) and together with semaglutide 2.4 mg, a combination named CagriSema. Today no cagrilintide product exists on the market: neither alone nor as CagriSema is it approved by the FDA or the EMA. Novo Nordisk submitted CagriSema to the FDA in December 2025 and expects a decision by late 2026; in Europe no submission has been publicly confirmed.
CAS: 1415456-99-3. Lyophilized powder: -20 °C, stable.
Articles
- Cagrilintide 10 mg: $145
For research use only. Not for human consumption.